allogeneic anti-mesothelin TRuC T-cell therapy (TCR2 Therapeutics)

N/A

Report date: 2025/01/26 18:22:14

Base Information

Drug Nameallogeneic anti-mesothelin TRuC T-cell therapy (TCR2 Therapeutics)

Drug Alias Nameallogeneic anti-mesothelin TCR T-cell therapy (TCR2 Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4]

Mechanisms of ActionMesothelin modulators

TargetsMesothelin

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTcr2 Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTcr2 Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A